Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants

Daix (France), New York City (New York, United States), July 9, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“ MASH ”), is pleased to announce the completion of the final step of the transactions previously announced on June 2, 2026 (the “ Combined Transaction ”) through the issuance of approximately 15.7 million new warrants ( bons de souscription d’actions ) (the " New EIB Warrants ") to the European Investment Bank (the " EIB ") and the surrender and cancellation of all remaining warrants originally issued to the EIB in January 2024 (the “ Legacy EIB Tranche B Warrants ”) that were not repurchased in the Combined Transaction.